Abstract Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts TKI sensitivity, while the latter is frequently annotated as potentially resistant based solely on genomic location, given the absence of direct functional evidence. Here we describe a 66-year-old female never-smoker with advanced lung adenocarcinoma harboring an EGFR p.G719A (exon 18) and p.H773L (exon 20) compound mutation.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile